ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

$ORICPress releaseAug 3, 2026, 4:05 PM ETRead the release

ORIC initiated the global Phase 3 registrational trial Himalayas-1 for rinzimetostat in mCRPC, partnering with Bayer to receive darolutamide at no cost. Cash, cash equivalents and investments totaled $387.6 million as of June 30, 2026, providing runway into the second half of 2028.

Key figures

Guidance: Runway into 2H 2028; rinzimetostat program update in 2H 2026; enozertinib clinical updates in 2H 2026
Shares outstanding: 108012388
Ga expenses q2 2026: 9000000
Rd expenses q2 2025: 30500000
Rd expenses q2 2026: 36300000
Cash and investments: 387600000

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.